Where Rallybio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Rallybio (NASDAQ:RLYB) has received 5 analyst ratings in the last quarter, with 3 bullish, 2 somewhat bullish, and none bearish. The average 12-month price target among these analysts is $16.4, with a high of $18.00 and a low of $14.00. This target is a 3.53% decrease from the previous target of $17.00. Analyst ratings are opinions on stock performance and are updated quarterly.
November 29, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rallybio has a positive outlook from analysts with 3 bullish and 2 somewhat bullish ratings. The average price target is now $16.4, down from $17.00.
The decrease in the average price target suggests a slight negative sentiment in the short term. However, the overall positive ratings from analysts indicate a generally optimistic outlook for RLYB, which could balance the impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100